FDA raises questions about Y-Mabs's children's cancer candidate
The treatment’s documented efficacy is based on thin data, and the US Food and Drug Administration is now taking a closer look at the company’s market authorization application.
by ulrich quistgaard, translated by daniel pedersen
Y-Mabs Therapeutics, a Danish-American biotech company, is under the microscope of the US Food and Drug Administration’s (FDA) ahead of the health authority’s special committee, the Oncology Drug Advisory Committee, or ODAC, meeting to review cancer drugs, reports industry media Endpoints News.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Y-mabs partner seeks launch of cancer drug in Brazil
For subscribers
Israel approves Y-mabs cancer drug
For subscribers
